Accuray announces FDA clearance of iDMS Data Management System

Accuray, a Sunnyvale, California-based radiation oncology company, announced Monday that it has received 510(k) clearance from the FDA for its iDMS Data Management System, a database that shares data between different Accuray delivery systems. The company views this new database as an upgrade to its entire TomoTherapy platform.

Lionel Hadjadjeba, Accuray’s senior vice president and chief commercial officer, said in a prepared statement that this makes the lives of specialists using Accuray’s solutions much easier.

“This most recent clearance reinforces Accuray's commitment to providing clinicians with options for seamless, fully integrated treatment planning and data management, enhancing department workflow efficiency,” Hadjadjeba said. “The common database will make it possible for clinicians to use any available Accuray treatment system, expanding patient access to the precision and treatment versatility of our advanced radiation therapy systems.”

The iDMA Data Management System was developed to integrate with numerous Accuray solutions, including the Radixact Treatment Delivery System, Accuray Precision™ Treatment Planning System and others.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The new F-18 flurpiridaz radiotracer is expected to help drive cardiac PET growth, but it requires waiting between rest and stress scans. Software from MultiFunctional Imaging can help care teams combat that problem.

News of an incident is a stark reminder that healthcare workers and patients aren’t the only ones who need to be aware around MRI suites.

The ACR hopes these changes, including the addition of diagnostic performance feedback, will help reduce the number of patients with incidental nodules lost to follow-up each year.